STOCK TITAN
  1. Home
  2. News
  3. NRXP

NRX Pharmaceuticals Inc - NRXP STOCK NEWS

Welcome to our dedicated news page for NRX Pharmaceuticals (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on NRX Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NRX Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NRX Pharmaceuticals's position in the market.

News
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
Rhea-AI Summary
NRx Pharmaceuticals (NASDAQ:NRXP) has received confirmation from Nasdaq that they have demonstrated compliance with the bid price requirement, ensuring the continued listing of the Company's securities. The Company is now focused on achieving four key milestones, including releasing data from trials in Suicidal Bipolar Depression and Chronic Pain, filing an NDA for IV Ketamine, and distributing shares of HOPE Therapeutics to existing shareholders. Recent unexpected achievements related to intravenous ketamine and complicated Urinary Tract Infection/pyelonephritis show promising potential for shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.75%
Tags
none
-
News
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
Rhea-AI Summary
NRx Pharmaceuticals, Inc. announced the pricing of a $2.0 million underwritten public offering of common stock at $3.30 per share. The company granted the underwriters an option to purchase additional shares. The offering is expected to close on April 19, 2024. NRx Pharmaceuticals plans to use the proceeds for working capital, general corporate purposes, and debt repayment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.75%
Tags
offering
-
News
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
Rhea-AI Summary
NRx Pharmaceuticals, Inc. announces a proposed underwritten public offering of common stock to raise funds for working capital, general corporate purposes, and debt repayment. The offering is subject to market conditions, with EF Hutton as the sole book-running manager. The net proceeds will be used for a national treatment protocol and safety database.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.75%
Tags
offering
News
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) announced new data on NRX-101 showing no damage to intestinal and vaginal flora in rodent models, potentially avoiding C. difficile infections. NRX-101 has FDA QIDP and Fast Track Designation for cUTI and Pyelonephritis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.79%
Tags
none
-
News
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
Rhea-AI Summary
NRx Pharmaceuticals (NASDAQ:NRXP) announced the development of a new, proprietary formulation of IV Ketamine, HTX-100. The formulation achieves a pH-neutral state, enabling both intravenous and subcutaneous administration. The company expects patent protection and has partnered with Nephron Pharmaceuticals to generate patents. HTX-100 is set to be marketed by HOPE Therapeutics, a subsidiary of NRx.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.3%
Tags
none
-
News
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Rhea-AI Summary
NRx Pharmaceuticals achieves data-lock in Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study with NRX-101, anticipates top-line data release in April 2024. Positive results lead to additional milestone payments and future development costs covered by partners. NRX-101 demonstrates potential for a broader patient population, with FDA designations and successful trials positioning it as a promising therapy for suicidal bipolar depression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
clinical trial
News
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
NRx Pharmaceuticals, Inc. announced significant milestones for 2024, including clinical trial data, NDA filing, share dividend, and commercial revenue forecasts. The company reported a 50% reduction in corporate overhead, 25% reduction in net loss, and an improvement in negative earnings per share. Key partnerships and advancements in NRX-101 development for bipolar depression, chronic pain, and urinary tract infection were highlighted. The company also established HOPE Therapeutics for IV Ketamine, with positive financial results and working capital additions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1012.52%
Tags
earnings
-
News
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights
Rhea-AI Summary
NRx Pharmaceuticals, Inc. announces anticipated financial results for FY 2023, highlighting improved negative EPS, positive cash flow projections by 2024, reduction in corporate indebtedness, key partnerships with Alvogen and Lotus Pharmaceuticals, successful clinical trial data for NRX-101 in bipolar depression, positive outcomes in ketamine studies, and plans for NDA filings and share dividends.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.96%
Tags
earnings
-
News
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) will undergo a reverse stock split on April 1, 2024, where every 10 pre-split shares will convert to 1 post-split share. The split-adjusted common stock will trade under the symbol NRXP on the Nasdaq Capital Market starting April 2, 2024. The reverse split aims to align share price with institutional investor preferences and enhance long-term shareholder value. Positive clinical trial data and future developments indicate potential for a forward stock split.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.96%
Tags
stock split
News
UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) to release Q4 and full year 2023 financial results on March 28, 2024. Conference call rescheduled to April 1, 2024, due to Good Friday holiday. Webcast and dial-in options available for participation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
conferences earnings
Stock NRXP logo
NRX Pharmaceuticals Inc

Nasdaq:NRXP

NRXP Rankings

#4940 Ranked by Market Cap
#4956 Ranked by Stock Gains
N/A Ranked by Dividends

NRXP Stock Data

49.00M
6.63M
30.04%
4.29%
4.44%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Delray Beach